GlassScriptPhysician profile
Hazem Samir-Moez
NPI 1992734214
$1,442.66
in general payments reported to CMS, 2019-2025
20 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.89 · 2020: $257 · 2021: $238 · 2022: $81.66 · 2023: $211 · 2024: $277 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $239.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $141.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.22 | 2023-2025 | |
| Abbvie INC. | $100.49 | 2023-2025 | Vraylar |
| Ironwood Pharmaceuticals, INC | $91.49 | 2020-2022 | |
| Fujifilm Healthcare Americas Corporation | $89.28 | 2021 | |
| Merck Sharp & Dohme LLC | $86.67 | 2019-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.98 | 2019-2024 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $55.05 | 2025 | |
| Axsome Therapeutics, INC. | $47.44 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $41.32 | 2024 | |
| Glaxosmithkline, LLC. | $39.61 | 2020-2024 | Trelegy Ellipta |
| Alkermes, INC. | $21.68 | 2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $21.13 | 2024 | Ajovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $16.90 | 2021 | |
| Redhill Biopharma INC. | $16.74 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.14 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $12.82 | 2025 | Voquezna |
| Novo Nordisk INC | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazem Samir-Moez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.